US 10,888,617 B2
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
Keith M. Faucher, Milford, NH (US); Suzanne Conroy, Dracut, NH (US); Theresa K. Albergo, Nashua, NH (US); and Joseph Bienkiewicz, Westford, MA (US)
Assigned to ATRIUM MEDICAL CORPORATION, Merrimack, NH (US)
Filed by ATRIUM MEDICAL CORPORATION, Merrimack, NH (US)
Filed on Nov. 21, 2017, as Appl. No. 15/819,304.
Application 15/819,304 is a division of application No. 13/843,068, filed on Mar. 15, 2013, granted, now 9,867,880.
Claims priority of provisional application 61/659,301, filed on Jun. 13, 2012.
Prior Publication US 2018/0140705 A1, May 24, 2018
Int. Cl. A61K 47/12 (2006.01); A61K 47/22 (2006.01); A61L 27/14 (2006.01); A61L 27/34 (2006.01); A61L 27/54 (2006.01); A61L 31/04 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01)
CPC A61K 47/12 (2013.01) [A61K 47/22 (2013.01); A61L 27/14 (2013.01); A61L 27/34 (2013.01); A61L 27/54 (2013.01); A61L 31/04 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); A61L 2300/606 (2013.01)] 21 Claims
 
1. A method of modulating the rate of release of one or more therapeutic agents from a coating material, the method comprising the steps of:
providing a biomaterial, wherein the biomaterial comprises fatty acids cross-linked to each other;
coupling a fixating material to the biomaterial to form the coating material, wherein the fixating material comprises material selected from the group consisting of sodium carboxymethylcellulose (Na-CMC), poly(ethylene oxide), poly(HEMA), poly(N-vinyl pyrrolidone), poly(acrylic acid), carboxymethyl cellulose (CMC), and chitosan, and wherein the fixating material is coupled to the biomaterial as a fixating material layer disposed on an outer surface of the biomaterial layer so that the biomaterial protonates the fixating material so as to alter a drug eluting property of the fixating material, and wherein at least the fixating material comprises one or more therapeutic agents; and
delivering, in a controlled manner, the one or more therapeutic agents in a patient from the coating material, wherein the rate of release of the one or more therapeutic agents from the coating material is based on at least the altered drug eluting property of the fixating material.